Clinical trials: Psychological Disorders
Depressive Disorder, Major, Anhedonia
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with…
- Trial name
- VENTURA-2 (NCT05550532)
- Testing
- Aticaprant
- Where
- 131 sites in United States, Argentina and 12 more
- Volunteers
- 444 people
- Sponsor
- Janssen Research & Development, LLC
Tobacco Dependence
Study to Determine if a New Nicotine Replacement Therapy Can Safely Help Smokers to Quit Smoking
This study is to see if a new nicotine replacement therapy safely helps people to quit smoking if it is used the way it would be if it were sold at the pharmacy and used at home.
- Trial name
- NCT01296698
- Testing
- Nicotine
- Where
- 19 sites in United States
- Volunteers
- 257 people
- Sponsor
- McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Drug Use Disorders, Illicit Drug Use
Addressing Barriers to Care for Substance Use Disorder Pilot Study
The Addressing Barriers to Care for Substance Use Disorder Pilot (ABC-SUD Pilot) was a randomized pilot study that preceded a larger trial.
- Conditions
- Drug Use Disorders, Illicit Drug Use, Alcohol-Related Disorders
- Trial name
- ABCSUD Pilot (NCT06317987)
- Testing
- Care Navigation
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Kaiser Permanente
Hypertension, Insomnia
To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia
The purpose of this study is to compare the effectiveness and safety of suvorexant versus placebo on sleep pressure and circadian rhythm in hypertensives with insomnia.
- Trial name
- Super1 (NCT02849184)
- Testing
- suvorexant
- Where
- 3 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Jichi Medical University
Opioid-use Disorder
PRimary Care Opioid Use Disorders Treatment (PROUD) Trial
Effective treatment for opioid use disorders (OUDs) requires medications. Two medications for treating OUDs-buprenorphine and injectable naltrexone-can be prescribed in primary care (PC).
- Trial name
- PROUD (NCT03407638)
- Testing
- PROUD Intervention
- Where
- 6 sites in United States
- Volunteers
- 377,373 people
- Sponsor
- Kaiser Permanente
Opioid Abuse
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
The primary objective of this study is to compare the relative abuse potential of two different doses of orally administered Acurox Tablets to orally administered immediate-release (IR) oxycodone HCl tablets in non-dependent…
- Trial name
- NCT01030406
- Testing
- 40/0mg taken first, 80/0mg taken first, 40/240mg taken first
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
ADHD, Growth
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
Previous NIH funded Attention Deficit Hyperactivity Disorder (ADHD) trials in children found that daily stimulant therapy produced sustained growth deficits.
- Trial name
- NCT01109849
- Testing
- behavior therapy, Extended release (ER) methylphenidate product, monitoring
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Florida International University
Alcohol Use Disorder, Couples
Building and Pilot Testing a Couples-based Smartphone Systems to Address Alcohol Use Disorder
This project will develop and pilot test a new smartphone-based system for AUD patients, their partners, and clinicians called PartnerCHESS. PartnerCHESS will integrate key features of ABCT and A-CHESS.
- Conditions
- Alcohol Use Disorder, Couples, Behavior, Addictive
- Trial name
- NCT04059549
- Testing
- PartnerCHESS, A-CHESS
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Wisconsin, Madison
Healthy
A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.
A pilot study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older adults.
- Trial name
- NCT04507126
- Testing
- Bacillus Calmette-Guerin (BCG)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Child Development, Developmental Disabilities
Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening
The purpose of this research study is to test the effectiveness of telephone-based early childhood developmental screening and care coordination, compared to usual care in a primary care pediatrics clinic.
- Conditions
- Child Development, Developmental Disabilities, Ambulatory Care, Screening
- Trial name
- NCT02495025
- Testing
- Telephone-based developmental screening and care coordination
- Where
- United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Schizophrenia
Relapse Prevention Study in Patients With Schizophrenia
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
- Trial name
- REPRIEVE (NCT01291511)
- Testing
- Iloperidone
- Where
- 63 sites in United States, India and 1 more
- Volunteers
- 635 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia, Diabetes Mellitus, Type 2
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia
The purpose of this study is to determine the efficacy of combining open-label extended release bupropion (flexible dosing up to 450mg target) and naltrexone (37.5mg) versus Bupropion and placebo along with a daily 500 calorie…
- Conditions
- Schizophrenia, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NBC (NCT03132571)
- Testing
- Naltrexone, Bupropion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Stress Disorders, Post-traumatic
Analyzing Female Trauma Exposed Responses to a Medication
This purpose of this study is to look at the safety of the experimental drug GSK561679 as well as its effects on PTSD symptoms, thinking and memory, startle reaction, stress hormones, and mental health symptoms in comparison to…
- Trial name
- AFTER (NCT01814332)
- Testing
- GSK561679
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- VA Office of Research and Development
Solid Carcinoma, Post Traumatic Stress Disorder
Psychological Care of Oncology Patients With Post-traumatic Stress in the Context of a COVID-19
In the context of the COVID-19 pandemic, concerns of the risk of infection may lead to fear, anxiety or psychological disorders that may become generalised and long-lasting, corresponding to post-traumatic stress disorder (PTSD).
- Conditions
- Solid Carcinoma, Post Traumatic Stress Disorder, Covid19
- Trial name
- COVIPACT 2 (NCT04747249)
- Testing
- Psychological support
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Centre Francois Baclesse
Schizophrenia
Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia
The Objective of this study is to investigate the long-term efficacy of intranasal oxytocin in improvement of symptoms in patients with schizophrenia who have residual symptoms dispute being on adequate treatment with…
- Trial name
- NCT02144155
- Testing
- Oxytocin: 24IU - 168 IU
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, San Diego
Autism Spectrum Disorders, Anxiety
An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders
The main objective of this exploratory 8-week pilot study is to evaluate the safety and efficacy of buspirone for the treatment of anxiety in youth (ages 6-17 years) with autism spectrum disorders.
- Trial name
- NCT01850355
- Testing
- Buspirone
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Pediatric
Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder (P06107 Has an Extension [P05898; NCT01349907])(P06107)
Efficacy and safety of asenapine for the treatment of bipolar I disorder (manic or mixed episodes) will be evaluated in participants between 10 and 17 years old, who are either hospitalized or non-hospitalized.
- Trial name
- NCT01244815
- Testing
- asenapine, Rescue medication
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Major Depressive Disorder
A Study for Participants With Major Depression
This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder.
- Trial name
- NCT00420004
- Testing
- LY2216684, Escitalopram
- Where
- 7 sites in United States, Romania
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder, Bipolar Disorder
Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder
This study proposes to examine the potential safety and efficacy of ziprasidone for patients with anxiety and bipolar disorder on anxiety outcomes, bipolar symptoms, and on measures of quality of life and resilience.
- Trial name
- NCT00374543
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.